Edition:
United Kingdom

Tigenix NV (TIG.OQ)

TIG.OQ on NASDAQ Stock Exchange Global Select Market

41.59USD
18 May 2018
Change (% chg)

$0.19 (+0.46%)
Prev Close
$41.40
Open
$41.50
Day's High
$41.59
Day's Low
$41.50
Volume
357
Avg. Vol
818
52-wk High
$43.94
52-wk Low
$16.72

Select another date:

Wed, Apr 25 2018

BRIEF-Takeda Says Announces Voluntary And Conditional Public Takeover Bid For Outstanding Shares,Warrants And American Depositary Shares Of Tigenix NV To Commence April 30, 2018

* SAYS ANNOUNCES VOLUNTARY AND CONDITIONAL PUBLIC TAKEOVER BID FOR OUTSTANDING SHARES, WARRANTS AND AMERICAN DEPOSITARY SHARES OF TIGENIX NV TO COMMENCE APRIL 30, 2018 Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)

BRIEF-Tigenix FY Operating Loss Widens to 53.2 Million Euros

* FY OPERATING LOSS OF EUR 53.2 MILLION VERSUS LOSS OF EUR 3.0 MILLION YEAR AGO

BRIEF-Tigenix And Takeda Announce Alofisel® (Darvadstrocel) Receives Approval To Treat Complex Perianal Fistulas In Crohn's Disease In Europe

* TIGENIX AND TAKEDA ANNOUNCE ALOFISEL® (DARVADSTROCEL) RECEIVES APPROVAL TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE IN EUROPE

BRIEF-Tigenix Says Received Transparency Notification From Jpmorgan Chase & Co​ On Jan 16

* ‍TRANSPARENCY NOTIFICATION PURSUANT TO ARTICLE 14 OF LAW OF MAY 2, 2007​‍

Japan's Takeda to acquire TiGenix for $630 mln

TOKYO, Jan 5 Japan's Takeda Pharmaceutical Co said on Friday it has agreed to buy Belgian biotech group TiGenix NV for 520 million euros ($628 million).

BRIEF-Tigenix Confirms Strategic Focus On Cx601 And Its Adipose Derived Stem Cell Platform

* CONFIRMS STRATEGIC FOCUS ON CX601 AND ITS ADIPOSE DERIVED STEM CELL (EASC) PLATFORM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tigenix Plans To Focus On Its eASC Platform And Product Candidates Cx601 And Cx611

* TIGENIX NV SAYS PLANS TO FOCUS ITS RESOURCES AND CAPABILITIES ON ITS EASC PLATFORM TECHNOLOGY AND ITS PRODUCT CANDIDATES CX601 AND CX611 Source text for Eikon: Further company coverage:

BRIEF-Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

* REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae​

* - MESOBLAST GRANTS ACCESS TO PATENTS TO SUPPORT COMMERCIALIZATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELL PRODUCT CX601 FOR TREATMENT OF FISTULAE​

BRIEF-JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​

* ‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​ Source text for Eikon: Further company coverage:

Select another date: